1. Home
  2. RA vs REPL Comparison

RA vs REPL Comparison

Compare RA & REPL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RA
  • REPL
  • Stock Information
  • Founded
  • RA 2016
  • REPL 2015
  • Country
  • RA United States
  • REPL United States
  • Employees
  • RA N/A
  • REPL N/A
  • Industry
  • RA Investment Managers
  • REPL Biotechnology: Pharmaceutical Preparations
  • Sector
  • RA Finance
  • REPL Health Care
  • Exchange
  • RA Nasdaq
  • REPL Nasdaq
  • Market Cap
  • RA 739.7M
  • REPL 816.4M
  • IPO Year
  • RA N/A
  • REPL 2018
  • Fundamental
  • Price
  • RA $13.14
  • REPL $10.80
  • Analyst Decision
  • RA
  • REPL Strong Buy
  • Analyst Count
  • RA 0
  • REPL 4
  • Target Price
  • RA N/A
  • REPL $17.00
  • AVG Volume (30 Days)
  • RA 280.8K
  • REPL 432.6K
  • Earning Date
  • RA 01-01-0001
  • REPL 11-12-2024
  • Dividend Yield
  • RA 14.73%
  • REPL N/A
  • EPS Growth
  • RA N/A
  • REPL N/A
  • EPS
  • RA N/A
  • REPL N/A
  • Revenue
  • RA N/A
  • REPL N/A
  • Revenue This Year
  • RA N/A
  • REPL N/A
  • Revenue Next Year
  • RA N/A
  • REPL $469.74
  • P/E Ratio
  • RA N/A
  • REPL N/A
  • Revenue Growth
  • RA N/A
  • REPL N/A
  • 52 Week Low
  • RA $11.89
  • REPL $4.92
  • 52 Week High
  • RA $17.32
  • REPL $12.97
  • Technical
  • Relative Strength Index (RSI)
  • RA 36.75
  • REPL 38.50
  • Support Level
  • RA $13.29
  • REPL $11.45
  • Resistance Level
  • RA $13.63
  • REPL $12.73
  • Average True Range (ATR)
  • RA 0.14
  • REPL 0.69
  • MACD
  • RA -0.03
  • REPL -0.16
  • Stochastic Oscillator
  • RA 20.49
  • REPL 8.82

About RA Brookfield Real Assets Income Fund Inc.

Brookfield Real Assets Income Fund Inc. is a diversified, closed-end management investment company. Its investment objective is to seek a high total return, through high current income and secondarily, through the growth of capital. The Fund seeks to achieve its investment objective by investing in the real asset class, which includes the following: Real Estate Securities; Infrastructure Securities; and Natural Resources Securities (collectively, Real Asset Companies and Issuers). The Firm manages separate accounts, registered funds, and opportunistic strategies for institutional and individual clients, including financial institutions, public and private pension plans, insurance companies, endowments and foundations, sovereign wealth funds, and high-net-worth investors.

About REPL Replimune Group Inc.

Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3.

Share on Social Networks: